Status:
COMPLETED
Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma
Lead Sponsor:
Duke University
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18-89 years
Brief Summary
The purpose of this study is to describe the real-world use of Belantamab Mafodotin - blmf (BLENREP) and associated patterns of care, including dosing and dose modification, eye care specialist visits...
Eligibility Criteria
Inclusion
- Age \> 18 years of age as of start of treatment with BLENREP
- Patients with a corresponding diagnosis code consistent with multiple myeloma seen at Duke.
- Patients with a record of starting treatment with BLENREP for RRMM between August 5, 2020 and November 22, 2022.
- Patients having healthcare encounters at Duke Cancer Institute (DCI) for at least 1-month after start of Blenrep treatment.
Exclusion
- Patients who were included in any clinical trial for BLENREP including expanded access clinical trials
- Age \> 89 years of age as of start of index therapy
Key Trial Info
Start Date :
September 18 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 7 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05986682
Start Date
September 18 2023
End Date
November 7 2023
Last Update
February 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University Medical Center
Durham, North Carolina, United States, 27705